Astellas US Holding, Inc. v. Federal Insurance Company

66 F.4th 1055
CourtCourt of Appeals for the Seventh Circuit
DecidedMay 3, 2023
Docket21-3075
StatusPublished
Cited by7 cases

This text of 66 F.4th 1055 (Astellas US Holding, Inc. v. Federal Insurance Company) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Astellas US Holding, Inc. v. Federal Insurance Company, 66 F.4th 1055 (7th Cir. 2023).

Opinion

In the

United States Court of Appeals For the Seventh Circuit ____________________ No. 21-3075 ASTELLAS US HOLDING, INC. and ASTELLAS PHARMA US, INC., Plaintiffs-Appellees,

v.

FEDERAL INSURANCE COMPANY, Defendant-Appellant. ____________________

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:17-cv-08220 — Franklin U. Valderrama, Judge. ____________________

ARGUED SEPTEMBER 9, 2022 — DECIDED MAY 3, 2023 ____________________

Before ROVNER, HAMILTON, and SCUDDER, Circuit Judges. HAMILTON, Circuit Judge. Plaintiffs Astellas US Holding, Inc. and Astellas Pharma US, Inc. (we can treat them here as one entity, Astellas) paid the federal government $100 million to settle potential claims for violations of the federal Anti- Kickback Statute and the federal False Claims Act. The poten- tial claims stemmed from Astellas’ contributions to so-called “patient assistance plans” to cover the costs of treatment with 2 No. 21-3075

an expensive new cancer drug. Astellas had a $10 million di- rectors-and-officers liability insurance policy with defendant Federal Insurance Company. The many questions raised in this appeal boil down to whether Illinois public policy forbids the liability insurer from covering part of its insured’s pay- ment to settle the federal government’s potential claims. The district court granted summary judgment for the insured, concluding that Illinois public policy does not forbid coverage of the settlement. In a thorough opinion, the court held that Federal owes Astellas the policy limit of $10 million. Astellas US Holding, Inc. v. Starr Indem. & Liab. Co., 566 F. Supp. 3d 879 (N.D. Ill. 2021). We affirm. Under Illinois law, a party may not obtain lia- bility insurance for genuine restitution it owes the victim of its intentional wrongdoing, but a party may obtain insurance for compensatory damages it may owe. Further, in cases of ambiguity and uncertainty, Illinois favors settlements and freedom of contract, and Federal wrote its insurance policy to try to extend insurance coverage to the very limit of what Illi- nois law would allow in such cases. Federal bears the burden of showing that the portion of the settlement payment for which Astellas seeks coverage is uninsurable restitution. Fed- eral has not carried that burden with evidence that would al- low a reasonable jury to decide in its favor. I. Facts for Summary Judgment & Procedural History A. Patient Assistance Plans To frame the controlling issue of Illinois insurance law, we must first provide some background about the insured’s dis- pute with the federal government. Drug manufacturers spon- sor “patient assistance plans” to help patients obtain needed No. 21-3075 3

medicines at affordable prices. In 2005, Congress amended the Medicare program to offer prescription drug coverage. In planning to implement the new legislation, the government raised concerns that patient assistance plans could be oper- ated in ways that could violate the federal Anti-Kickback Stat- ute, 42 U.S.C. § 1320a-7b, and the False Claims Act, 31 U.S.C. § 3729, by effectively rewarding doctors and patients for choosing to use particular drugs. See Special Advisory Bulletin: Patient Assistance Programs for Medicare Part D Enrollees, 70 Fed. Reg. 70623-03 (Nov. 22, 2005). The government cautioned that patient assistance plans would need to be “properly structured” to avoid illegally channeling contributions by drug makers to patients and impermissibly influencing their drug choices. Id. at 70626, 70627. B. Astellas’ Contributions to Patient Assistance Programs In 2012 plaintiff Astellas launched Xtandi, a so-called “an- drogen receptor inhibitor” used to treat metastatic prostate cancer that has not responded to surgery. Initially priced at $7,800 per month, Xtandi prescriptions were to be covered by Medicare up to about $6,000 per month, leaving patients with a steep monthly co-pay of about $1,800. When it launched Xtandi, Astellas began making contri- butions to a patient assistance plan run by the Chronic Dis- ease Fund. A few months later, Astellas also started contrib- uting to another plan run by the Patient Network Foundation. Apparently, these two funds kept running out of money. In May 2013, an Astellas marketing executive encouraged both the Chronic Disease Fund and the Patient Network Founda- tion to create special funds that would provide co-pay assis- tance for only androgen receptor inhibitors like Xtandi and just a few other medications. 4 No. 21-3075

In-house lawyers at Astellas and the two patient assistance plans and several outside law firms considered the govern- ment’s November 2005 regulatory guidance. The lawyers blessed the plan for such narrowly targeted funds. The Chronic Disease Fund and the Patient Network Foundation then set up funds limited to helping patients who needed an- drogen receptor inhibitors. In July 2013, Astellas began mak- ing donations to these funds. Astellas stopped contributing to them after a few months, at the end of 2013. During those months, Astellas contributed about $27 million to the two funds. Astellas continued contributing to broader prostate- cancer funds until 2016. Astellas contributed a total just shy of $130 million to the targeted and broader funds. C. The Department of Justice Investigation and the Settlement The United States Department of Justice began investigat- ing Astellas’ contributions to patient assistance plans for po- tential health care offenses. In April 2017, the Astellas market- ing executive at the center of the inquiry made a “proffer” to the Department. He acknowledged that he had “hoped” and “expected” that the contributions would produce financial benefits for Astellas. But he maintained that the “primary pur- pose of the donations … was charitable,” and he asserted that Astellas had made no efforts to calculate “a return on invest- ment.” In September 2017 the Department of Justice issued a more specific and detailed Civil Investigative Demand to the same executive. One month later, Astellas agreed with the govern- ment to toll the relevant statutes of limitations for potential litigation relating to Astellas’ possible violations of the False Claims Act, the Anti-Kickback Statute, and the criminal health No. 21-3075 5

care fraud provision of the Health Insurance Portability and Accountability Act, 18 U.S.C. § 1347. Early in 2018, Astellas authorized its outside counsel to begin settlement negotiations. The government initially esti- mated its damages at approximately $460 million. As negoti- ations continued, the government narrowed its focus to Med- icare losses attributable to Astellas’ contributions to only the narrowly focused androgen receptor inhibitor funds. The government disclosed a new, narrower damages estimate of $82 million. Applying a standard multiplier, the government sought approximately $164 million. In April 2019, Astellas set- tled with the government for $100 million, $50 million of which was labeled as “restitution to the United States” for tax reasons discussed below. D. The Federal Insurance Policy and the Coverage Dispute After agreeing to the settlement, Astellas turned to several liability insurers, including Federal, to help cover portions of the $100 million settlement payment. Astellas’ directors-and- officers excess liability insurance policy with Federal had a policy limit of $10 million. Astellas demanded the policy limit from Federal. Federal and the other insurers denied coverage. Astellas then filed this suit for breach of the insurance con- tracts.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
66 F.4th 1055, Counsel Stack Legal Research, https://law.counselstack.com/opinion/astellas-us-holding-inc-v-federal-insurance-company-ca7-2023.